ReviewNaunyn-Schmiedeberg's archives of pharmacology2020

Adrenal insufficiency is a contraindication for omalizumab therapy in mast cell activation disease: risk for serum sickness.

G J Molderings et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.